Paraneoplastic syndromes (PS) represent a large spectrum of symptoms, associated with malignant diseases. PS can be diagnosed in asymptomatic patients with occult carcinoma, clinically active cancer, and during clinical remission, suggesting a recurrence of the neoplasm. The underlying mechanisms of PS are not completely understood but several authors have suggested that the increased production of biologically active immune factors and cytokines from the neoplastic cells may underlie the etiology of PS. Although rare, the renal involvement of patients with prostatic carcinoma has been reported. The most common paraneoplastic-associated glomerulopathy in prostatic cancer is the membranoproliferative glomerulonephritis with nephrotic syndrome (NS). In this review, we aimed to discuss the incidence of nephrotic syndrome secondary to prostatic carcinoma, its challenging diagnosis, clinical manifestation, and treatment.
References
[1]
Pelosof, L.C. and Gerber, D.E. (2010) Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment. Mayo Clinic Proceedings, 85, 838-854. https://doi.org/10.4065/mcp.2010.0099
[2]
Lien, Y.H. and Lai, L.W. (2011) Pathogenesis, Diagnosis and Management of Paraneoplastic Glomerulonephritis. Nature Reviews Nephrology, 7, 85-95. https://doi.org/10.1038/nrneph.2010.171
[3]
Wagrowska-Danilewicz, M. and Danilewicz, M. (2011) Nephrotic Syndrome and Neoplasia: Our Experience and Review of the Literature. Polish Journal of Pathology, 62, 12-18.
Monga, D. and Jhaveri, K.D. (2016) Glomerular Diseases and Cancer. American Society of Nephrology Onco-Nephrology Curriculum, 1-9.
[6]
Pani, A., Porta, C., Cosmai, L., Melis, P., Floris, M., Piras, D., Gallieni, M., Rosner, M. and Claudio Ponticelli, C. (2016) Glomerular Diseases and Cancer: Evaluation of Underlying Malignancy. Journal of Nephrology, 29, 143-152. https://doi.org/10.1007/s40620-015-0234-9
[7]
Matsuura, H., Sakurai, M. and Arima, K. (2000) Nephrotic Syndrome Due to Membranous Nephropathy Associated with Metastatic Prostate Cancer: Rapid Remission after Initial Endocrine Therapy. Nephron, 84, 75-78. https://doi.org/10.1159/000045542
[8]
Nenova, I.S., Valcheva, M.Y., Beleva, E.A., Tumbeva, D.Y., Yaneva, M.P., Rancheva, E.L. and Grudeva-Popova, Z.G. (2016) Autoimmune Phenomena in Patients with Solid Tumors. Folia Medica, 58. https://doi.org/10.1515/folmed-2016-0026
[9]
Galloway, J. (1922) Remarks on Hodgkin’s Disease. British Medical Journal, 2, 1201-1208. https://doi.org/10.1136/bmj.2.3234.1201
[10]
Stuart, K., Fallon, B.G. and Cardi, M.A. (1986) Development of the Nephrotic Syndrome in a Patient with Prostatic Carcinoma. American Journal of Medicine, 80, 295-298. https://doi.org/10.1016/0002-9343(86)90026-4
[11]
Lee, J.C., Yamauchi, H. and Hopper Jr., J. (1966) The Association of Cancer and the Nephrotic Syndrome. Annals of Internal Medicine, 64, 41-51. https://doi.org/10.7326/0003-4819-64-1-41
[12]
Cohen, E.P., Batuman, V., et al. (2016) Nephrotic Syndrome. Medscape.
[13]
Pai, P., Bone, J.M., McDicken, I. and Bell, G.M. (1996) Solid Tumour and Glomerulopathy. The Quarterly Journal of Medicine, 89, 361-367. https://doi.org/10.1093/qjmed/89.5.361
[14]
Lefaucheur, C., Stengel, B., Nochy, D., Martel, P., Hill, G.S., Jacquot, C., Rossert, J., for Gn-Progress Study Group (2006) Membranous Nephropathy and Cancer: Epidemiologic Evidence and Determinants of High-Risk Cancer Association. Kidney International, 70, 1510-1515. https://doi.org/10.1038/sj.ki.5001790
[15]
Haskell, L.P., Fusco, M.J., Wadler, S., Leonarda, B., Sablay, L.B. and Mennemeyer, R.P. (1990) Crescentic Glomerulonephritis Associated with Prostatic Carcinoma: Evidence of Immune-Mediated Glomerular Injury. The American Journal of Medicine, 88, 189-192.
